Second medical use: a regulatory perspective

As compound patents and regulatory data protection for medicinal products expire, pharmaceutical companies increasingly look to develop new uses for their products. This strategy usually involves filing second medical use patents to protect the invention and research investment.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

EU court under pressure to define SPC limits in patent row

24 April 2026 An opinion has put pressure on the CJEU to clarify a long-running grey area that could change the game for how drug makers secure supplementary protection certificates across Europe.

Europe

INTA 2026: In-house tips on what to do in London

21 April 2026 With the start of the first-ever INTA Annual Meeting held in the UK capital just weeks away, in-house IP counsel share their favourite ways to spend downtime in the city.

Europe

IP finance gap risks startup exodus, EUIPO warns

13 April 2026 New report finds that just 13% of IP-owning firms have sought financing through their assets, with billions in potential funding left untapped, as structural barriers persist.

More features

EU court under pressure to define SPC limits in patent row

Amneal acquires biopharma ahead of $300bn patent wave

Health tech firm sues Nvidia-backed rival over ‘brazen’ theft

Litigator from Brown Rudnick moves firms to chair practice

INTA 2026: In-house tips on what to do in London

Penile implant maker’s $17m trade secret award unravels

Appeals court eases Teva’s headache with reversal

Baker McKenzie strengthens IP bench with new German lead

Second medical use: a regulatory perspective

More on this story

Editor's picks

Editor's picks

More features